# Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)

> **NCT02287311** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Baylor College of Medicine** · enrollment: 38 (actual)

## Conditions studied

- Hodgkin Disease
- Non-Hodgkin Lymphoma
- Severe Chronic Active Epstein Barr Virus
- T/NK-lymphoproliferative Disease
- Nasopharyngeal Carcinoma
- Smooth Muscle Tumor

## Interventions

- **BIOLOGICAL:** MABEL CTLs
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT02287311
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-02
- **Primary completion:** 2024-01-12
- **Final completion:** 2029-03
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02287311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02287311, "Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT02287311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*